# Completion Instructions:

Complete this questionnaire by providing all the requested information and documentation. All information/documentation provided will be treated confidentially.

The completed questionnaire must be signed before returning.

If you have any questions or need clarification for questions on this form, contact RA Janssen RnD ASL (RA-Janssen\_RnD\_ASL@ITS.JNJ.com) mailbox.

# Section 1: Supplier Contact Information

|  |  |  |  |
| --- | --- | --- | --- |
| **Supplier Company Legal Name:** | | | |
| **Service Location Address(es) (Street, City, Region/State, Market/Location, Zip/Postal Code): (if multiple locations/satellite locations include all addresses as applicable):** | | | |
| **Headquarters Address (Street, City, Region/State, Market/Location, Zip/Postal Code):** | | | |
| **Description of service(s):** | | | |
| Supplier Personnel | Name | E-Mail | Phone |
| **Business Contact** |  |  |  |
| **Quality Assurance (QA) Contact** |  |  |  |
| **IT Contact** |  |  |  |
| ***(Additional contact, role)*** |  |  |  |
| ***(Additional contact, role)*** |  |  |  |

# Section 2: Supplier Documents

| **No.** | **Question** | **Comment** | **Document Reference #** |
| --- | --- | --- | --- |
| 2.1 | Provide a copy of the company’s organizational chart.  In the comment field:   * Provide the number of full-time equivalent and contracted employees. |  |  |
| 2.2 | Provide an index of the company’s documented controlled procedures (including but not limited to Standard Operating Procedures [SOPs], Policies, and Work Instructions) for every location including the effective date and version number applicable to the services you are providing including:   * Sites where the procedures are applicable, * Those that define your Quality Management Systems (QMS), * IT documented controlled procedures including how you build, manage, and operate your computer applications/computer systems. |  |  |
| 2.3 | Provide a copy or list of the current system inventory.  In the comment field:   * Describe if the company made updates, developed, or implemented new computerized systems/applications. * Indicate what type of system(s) have been implemented or updated. |  |  |
| 2.4 | Provide a copy of all certification/accreditation documents including technical attachments (e.g., scope of certificate).  In the comment field:   * Describe if the Company has had any changes to the quality accreditation(s) or certifications. |  |  |

#

# Section 3: Supplier Information

(Document the changes that occurred within the last 5 years or as specified in the question below.)

| **No.** | **Question** | **Yes** | **No** | **NA** | **Comment** |
| --- | --- | --- | --- | --- | --- |
| 3.1 | List the services being provided to J&J Innovative Medicine by the company.  Indicate the applicable GxP discipline(s) (GCP, GLP, PV, GCLP) for each service being provided. |  |  |  |  |
| 3.2 | Did the company discontinue providing any service(s) to J&J Innovative Medicine in the past 18 months?  If yes, indicate which service(s) has been discontinued and when. |  |  |  |  |
| 3.3 | Company Significant Changes  Examples include but are not limited to:   * Changes to the internal organizational structure (i.e. quality organization), * Change in ownership/legal name * Facility/site relocation * Merger/acquisition * Quality Management System (QMS) changes * Changes to the company operation processes | | | | |
| 1. Did the company have significant changes that occurred in the past 12 months?  If yes, summarize the change(s) in the comment field. |  |  |  |  |
| 1. Did the company have significant changes that occurred over the past 13-36 months?  If yes, summarize the change(s) in the comment field. |  |  |  |  |
| 3.4 | Has the company records management/ retention process been updated or changed?   * If yes, describe what updates to your standard retention timeframe/ process for records have been made in the Comment field. |  |  |  |  |
| 3.5 | Have there been any major/significant changes to the Quality Control (QC) procedure(s), Quality Assurance (QA) function and/or QMS process within the company?   * If yes, summarize the change(s) in the Comment field. |  |  |  |  |
| 3.6 | Inspection History | | | | |
| 1. Provide inspection history for the past 5 years (including type of inspection/authority and dates). |  |  |  |  |
| 1. Were there any major/critical finding(s), finding(s) related to data integrity, official action indicated, warning letter, loss of accreditation/certification? |  |  |  |  |
| 1. Was voluntary action indicated? |  |  |  |  |
| 1. Were there any major/critical observations or actions indicated? |  |  |  |  |
| 1. Was (re)certification achieved (if applicable). |  |  |  |  |
| 3.7 | Assessment of changes in regulations and regulatory guidelines. (e.g., ICH E6, 21 CFR Part 312, 21 CFR 58, OECD, 40 CFR 160, GPvP) | | | | |
| 1. Does the company ensure compliance when regulations and/or guidelines are revised?    * If yes, describe the approach in the comment field. |  |  |  |  |
| 1. Has the company recently assessed regulatory guidelines/regulation changes?    * If yes, list regulatory guideline/regulation changes assessed in the somment field. |  |  |  |  |
| 1. List ongoing/planned/implemented assessments of (upcoming) regulatory changes in the comment field. |  |  |  |  |
| 3.8 | Have there been any significant issue escalation(s) and resolution(s) to incidents that occurred in the past 18 months?  If yes, provide the following in the comment field:   * Provide an aggregate number of each issue type. Including notification to management of an issue, including but not limited to: * A notable departure from GxP? * A notable departure from the company and/or trial procedure? * An issue that presents a serious risk for the validity or integrity of the data, presents a serious risk for the subject(s), or requires immediate escalation. * Animal Welfare Issue/Concern. |  |  |  |  |
| 3.9 | Has the company escalated any significant quality issues (e.g., an issue that significantly impacts the safety and/or rights of patients or the overall outcome of a clinical trial) and/or missed any contractual obligations for J&J during the last 18 months?  If yes, provide the following information in the comment field:   * Indicate how many notifications were made and the type of each notification. * Indicate how many study plan-relatedimpactful incidents and/or errors during services provided in the last 18 months. |  |  |  |  |
| 3.10 | Has the company updated, changed and/ or tested the disaster recovery plan (DRP) or Business Continuity Plan (BCP) process/procedure?   If yes, indicate what changes have been made including a summary of the testing outcomes in the Comment Field. |  |  |  |  |
| 1. When was the BCP/DRP last reviewed and updated? |  |  |  |  |
| 1. When was the BCP/DRP last tested and what was the outcome? |  |  |  |  |
| 3.11 | Has the company changed or modified the Software Development Life Cycle (SDLC) process?  If yes, describe what changes have been made to the SDLC process in the Comment field. |  |  |  |  |
| 3.12 | Does the company have updated controls in place to prevent unauthorized access and disruptions for computer applications (i.e., virus protection, intrusion protection, firewalls, etc.)?  If yes, describe the changes in the Comment field. |  |  |  |  |
| 3.13 | Has the company updated or changed the Change Control process?  If ye, describe the changes made in the Comment field. |  |  |  |  |
| 3.14 | Has the company made any changes to the training program for employees?  If yes, describe the changes in the Comment field. |  |  |  |  |

# Section 4: Supplier Signature

|  |  |
| --- | --- |
| **Checklist completed by:** | |
| Name (print): |  |
| Title: |  |
| Date: (DD/MMM/YYYY) |  |
| eSignature |  |